Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?-Reference-Cited by-同舟云学术

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

Published:2007-10-26 Issue:4 Volume:27 Page:541-542
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Tektonidou Maria G.,Skopouli Fotini N.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-007-0775-y.pdf

Reference9 articles.

1. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602–610

2. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376

3. Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J (2005) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 23:891–892

4. Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C (2006) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 45:1446–1448

5. Bagalas V, Kioumis I, Argyropoulou P, Patakas D (2007) Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 26:1344–1345

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Klinisch‐pathologische Eigenschaften kutaner und mukokutaner Leishmaniose bei mit TNF‐α‐Inhibitoren behandelten Patienten;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-05

2. Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF‐α inhibitors;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-04-12

3. Timeline and Infectious Disease Evaluation of Candidates to New Therapies;Infectious Complications in Biologic and Targeted Therapies;2022

4. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression;PLOS Neglected Tropical Diseases;2019-08-30

5. Leishmaniasis and biologic therapies for rheumatologic diseases: a concise review;Gazzetta Medica Italiana Archivio per le Scienze Mediche;2018-10